Kyowa Hakko Bio announced that it has integrated its former German affiliate into its operations. As part of this transition, Kyowa Hakko Bio Italia (KHIT) is now positioned as Kyowa’s central commercial hub for Europe, the Middle East, and Africa.

With a legacy in Italy, southern Europe, and Middle Eastern markets, KHIT will assume a broader regional role, focusing on Kyowa’s Health Science growth strategy, particularly in the Cognizin Citicoline segment for health science and dietary supplements.

Nicola Urso, a seasoned executive with 25 years of experience in the company, has been appointed president of KHIT, after playing a key role in guiding the company through several challenges over the years, Kyowa Hakko reported. Urso will lead KHIT in expanding into new markets, improving its digital presence, and talent acquisition for its scientific and commercial operations.

“This evolution marks a new chapter in our European journey,” said Urso. “With a more agile structure and a clear regional remit, KHIT is poised to deliver greater scientific value to customers across EMEA, faster and more effectively than ever before.”

KHIT will establish a dedicated scientific marketing function to enhance its partnerships and communication across the region. This new function, led by Eri Nakazaki, PhD, senior manager and head of scientific marketing and business development, will work closely with the company’s global R&D and commercial teams to translate scientific research into actionable claims, marketing materials, and customer-facing programs.

With these changes, KHIT will become the single commercial platform for Europe, the Middle East, and Africa, having local GMP stock approved by local authorities, enabling faster decision-making and consistency. KHIT will increase its focus on the Citicoline portfolio and have a greater ability to co-develop and scale solutions with global food and nutraceutical companies.

“By combining world-class science with sharper execution, Kyowa Hakko Bio Italia is set to elevate Kyowa’s presence and performance across EMEA,” said Urso. “We’re committed to turning differentiated science into long-term value for our customers.”